To further promote the in-depth integration of global capital with pharmaceutical and investment industry in China under the pandemic, China Pharmaceutical Innovation and Research Development Association (PhIRDA) and iMeta Health Information Consulting will co-host the Virtual 2021 China BioMed Forum on January 12-13, 2021 during the 39th J.P. Morgan Healthcare Conference. The forum will focus on the new dynamics and trends of global investment and financing, select high-quality innovative companies and demonstrate the achievements of China’s pharmaceutical innovation to domestic and foreign investors and entrepreneurs, promote international cooperation in the field of pharmaceutical innovation and jointly build new pattern of the pharmaceutical industry in the post-pandemic era.

2021年摩根大通医疗健康周

中国医药创新投资论坛日程

2021 China BioMed Forum Agenda

J.P. Morgan Week 2021

主办单位：

中国医药创新促进会、艾美达（北京）医药信息咨询有限公司

Hosts:

China Pharmaceutical Innovation and Research Development Association (PhIRDA)

iMeta Health Information Consulting Co., Ltd.

承办单位：中国药促会医药创新投资专业委员会

Organizer: PhIRDA Pharmaceutical Innovation Investment Specialty Committee

1月12日（周二）论坛

Tue Jan 12, 9-11am CST (Mon Jan 11, 17-19pm PST)

09:00-09:05主持人介绍：胡雪峰，中国医药创新促进会医药创新投资专业委员会秘书长

Host: Hu Xuefeng, Secretary-General of PhIRDA Pharmaceutical Innovation Investment Specialty Committee

09:05-09:20主旨报告：浅谈中国医药创新发展

报告人：宋瑞霖，中国医药创新促进会执行会长

Keynote Speech: Brief Introduction on Pharmaceutical Innovation Development in China

Speaker: Song Ruilin, Executive President of PhIRDA

09:20-10:10专题讨论1：中国生物医药投资与合作未来趋势

Panel 1: Trends of Pharmaceutical Investment & Cooperation in China

主持人：黄国滨，摩根大通全球投资银行中国区主管、董事总经理

Moderator: Houston Huang, Managing Director, Head of China Global Investment Banking at J.P. Morgan

讨论嘉宾Panelists

吴晓滨，百济神州中国区总经理兼公司总裁

Wu Xiaobin, General Manager of China & President of BeiGene

梁颕宇，启明创投主管合伙人

Nisa Leung, Managing Partner of Qiming Venture Partners

方  敏，华平投资合伙人、中国医疗健康投资负责人

Fang Min, Managing Director & Head of Healthcare Investment of Warburg Pincus

张  丹，昆翎联合创始人兼首席战略官

Zhang Dan, Co-Founder & Chief Strategy Officer of ClinChoice

10:10-11:00主题讨论2：中国医药创新发展趋势与挑战

Panel 2: Trends and Challenges of Pharmaceutical Innovation Development in China

主持人：蔡大庆，夏尔巴投资创始管理合伙人

Moderator: Darren Cai, Founder & Managing Partner of Sherpa Venture Capital

讨论嘉宾Panelists

王  磊，阿斯利康全球执行副总裁、国际业务中国总裁

Leon Wang, Executive Vice President, International & China President of AstraZeneca

李怡平，上海药明巨诺生物科技有限公司联合创始人、董事长兼首席执行官

James Li, Co-Founder, Chairman & CEO of JW Therapeutics

盛泽林，苏州泽璟生物制药股份有限公司董事长、总经理

Sheng Zelin, Chairman of the Board & CEO of Suzhou Zelgen Biopharmaceuticals

田  源，元明资本创始合伙人

Lawrence Tian, Founding Partner of YuanMing Capital

李凯军，醴泽资本管理合伙人

Kevin Li, Managing Partner of LYZZ Capital

1月13日（周三）生物医药企业路演BioMed Roadshow

Wed Jan 13, 9-12am CST (Tue Jan 12, 17-20pm PST)

09:00-09:05 主持人介绍：胡雪峰，中国医药创新促进会医药创新投资专业委员会秘书长

Host: Hu Xuefeng, Secretary-General of PhIRDA Pharmaceutical Innovation Investment Specialty Committee

09:05-09:20 路演1：加科思，专注创新肿瘤疗法的自主发现和开发

Jacobio, Focusing on the In-house Discovery and Development of Innovative Oncology Therapies

汇报人：王印祥，加科思药业董事长兼CEO

Speaker: Wang Yinxiang, Chairman & CEO of Jacobio Pharmaceutical

09:20-09:35 路演2：荣昌生物：专注创新生物药物，满足临床需求

RemeGen: Focusing on Innovative Biologics for Unmet Medical Need

汇报人：房健民，荣昌生物联合创始人、首席执行官兼首席科学官

Speaker: Fang Jianmin, Co-Founder, CEO & CSO of RemeGen

09:35-09:50 路演3：泽璟制药的差异化产品管线和新药研发策略

Differentiated Pipeline and Research & Development Strategy in Zelgen

汇报人：盛泽林，苏州泽璟生物制药股份有限公司董事长、总经理

Speaker: Sheng Zelin, Chairman of the Board & CEO of Suzhou Zelgen Biopharmaceuticals

09:50-10:05 路演4：和铂医药——依托全球核心技术平台 引领生物医药产业发展

Harbour BioMed - Leading the Next Wave of Immunotherapies in Oncology and Immunology

汇报人：王劲松，和铂医药创始人、董事长兼首席执行官

Speaker: Wang Jinsong, Founder, Chairman & CEO of Harbour BioMed

10:05-10:20 路演5：百创新药，济世惠民——百济神州公司介绍

Cancer has No Border, Neither Do We: Beigene Corporate Presentation

汇报人：梁恒，百济神州首席财务官兼首席战略官

Speaker: Howard Liang, CFO & CSO of BeiGene

10:20-10:35 路演6：开拓药业——聚焦肿瘤和雄激素受体(AR)相关疾病领域

Kintor Pharmaceutical Limited - Focus on Oncology and Androgen Receptor (AR) Related Diseases

汇报人：卢燕，开拓药业首席财务官

Speaker: Lucy Lu, CFO of Kintor Pharmaceutical

10:35-10:50 路演7：上海挚盟医药科技有限公司——一个具有大梦想的小公司

Shanghai Zhimeng Biopharma - A Small Company with a Big Dream

汇报人：张志军，挚盟医药首席科学官

Speaker: Zhang Zhijun, CSO of Zhimeng Biopharma

10:50-11:05 路演8：Valitor：利用高分子生物物理学发展卓越的生物技术疗法

Valitor: Harnessing Polymer Biophysics to Develop Superior Biotechnology Therapeutics

Speaker: Wesley M. Jackson, CEO of Valitor

11:05-11:20 路演9：Amplicore——找回活动力的再生医学新解方

Amplicore, Restoring Mobility

汇报人：林嘉盈，总裁兼执行长

Speaker: C. James Lin, President & CEO of Amplicore

11:20-11:35 路演10：ARB202：双特异性抗体治疗晚期胃肠道癌

ARB202: A Novel Bispecific Antibody to Treat Advanced GI Cancers

汇报人：陆满晴，Arbele首席执行官

Speaker: John Luk, CEO of Arbele

11:35-11:50 路演11：肿瘤药物输送的未来

The Future of Oncology Drug Delivery

Speaker: Earle Holsapple, President & Co-Founder of Scitech Development, LLC

               Brian Leyland-Jones, CMO of Scitech Development, LLC

11:50-12:05 路演12：QR052：治疗难治性慢性咳嗽的高选择性P2X3拮抗剂的研发

QR052: A highly Selective P2X3 Antagonist - Developed for the Treatment of Refractory Chronic Cough (RCC)

汇报人：陈永凯，朗来科技首席执行官

Speaker: Chen Yongkai, CEO of Createrna Science & Technology